Location: United States
Total raised: $157.8M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2026 | Series B | $115M | Janus Hend... |
| 07.09.2022 | Series D | $42.8M | - |
Mentions in press and media 10
| Date | Title | Description |
| 17.02.2026 | ILiAD Biotechnologies Secures $115M to Accelerate Advanced Pertussis Vaccine Development | ILiAD Biotechnologies, a clinical-stage biotech firm, raised $115 million in Series B funding. RA Capital Management led the investment. Janus Henderson and BNP Paribas Asset Management Alts also participated. The capital will advance BPZE1... |
| 11.02.2026 | ILiAD Biotechnologies Raises $115M in Series B Funding | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotech company, raised $115M in Series B funding. The round was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Man... |
| 10.02.2026 | ILiAD Biotechnologies snags $115M series B for whooping cough vaccine | ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation whooping cough vaccine candidate. Led by RA Capital Management, and with participation from new partners Janus Hende... |
| 10.02.2026 | ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Seri... |
| 03.12.2025 | ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model | ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The... |
| 07.09.2022 | ILiAD Biotechnologies of Weston closes $42.8M Series D | Facebook Tweet Pin LinkedIn Email ILiAD Biotechnologies, a clinical stage biotech company based in Weston, raised $42.8M in Series D funding. The round was led by New York-based Knott Partners. Under CEO and founder Dr. Keith Rubin, ILiAD B... |
| 06.09.2022 | ILiAD Biotechnologies Closes $42.8M Series D Financing | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotechnologies company, raised $42.8M in Series D funding. The round was led by Knott Partners. The company intends to use the funds to conduct a Phase 2b Human Challenge study to de... |
| 06.09.2022 | ILiAD Biotechnologies Scores $42.8M | WESTON, FL, ILiAD Biotechnologies today announced the closing of a $42.8 million Class D round of financing. >> Click here for more funding data on ILiAD Biotechnologies >> To export ILiAD Biotechnologies funding data to PDF... |
| 19.12.2018 | ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center | WESTON, Fla.–(BUSINESS WIRE)–December 19, 2018– ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the initial closing of a Class C fi... |
| - | ILiAD Biotechnologies | “ILiAD Biotechnologies is a clinical stage biotechnology company dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis. Our lead candidate, BPZE1, represents the most advanced next generation pertussis vaccine... |